Oculis Holding AG (OCS)

Market Cap	910.64M
Revenue (ttm)	960,668
Net Income (ttm)	-135.09M
Shares Out	52.34M
EPS (ttm)	-2.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,356
Open	17.44
Previous Close	17.66
Day's Range	17.21 - 17.45
52-Week Range	11.78 - 23.08
Beta	0.11
Analysts	Strong Buy
Price Target	35.75 (+105.46%)
Earnings Date	Nov 6, 2025

About OCS

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: OCS
• Website: https://oculis.com

Financial Performance

In 2024, Oculis Holding AG's revenue was 686,000, a decrease of -22.31% compared to the previous year's 883,000. Losses were -85.78 million, -3.41% less than in 2023.

Financial numbers in CHF

Analyst Summary

According to 4 analysts, the average rating for OCS stock is "Strong Buy." The 12-month stock price target is $35.75, which is an increase of 105.46% from the latest price.

Price Target

$35.75

(105.46% upside)

Analyst Consensus: Strong Buy